Report Overview

The Brazil Hemophilia A Therapeutics market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Brazil is the country with the third largest population of people with hemophilia. Hemophilia A is a bleeding disorder resulting from the inherited deficiency of coagulation factor VIII (FVIII), which is transmitted recessively and linked to the X chromosome. Patients tend to have recurrent bleeding of varying severity, which occurs spontaneously or posttraumatically in any organ or tissue. Over 90% of the hemorrhagic events involve hemarthrosis, intra-articular bleeding that begins to occur in the first years of life. When recurrent and untreated, or inadequately treated, hemarthrosis results in permanent damage to articular cartilage, leading to deforming and crippling arthropathy even in the second decade of life.



Market Drivers

Major reason for the market growth is due to government initiative and better reimbursement policies in the sector. Free comprehensive care, maintaining an updated registry of patients, documenting the prevalence of complications, and assessing the effectiveness of resource use are indispensable elements in the design of a well-coordinated national program by SUS. Brazilian Hemophilia A market is also driven by factors such as the growing prevalence of the disease and the increasing usage of recombinant products.

Advancements in technology have brought novel regulating factors that are also helping in the growth of the market. Rising investments into Research and developments are also a major factor supporting the market growth.